152 related articles for article (PubMed ID: 35422284)
1. Co-delivery of doxorubicin and CRISPR/Cas9 or RNAi-expressing plasmid by chitosan-based nanoparticle for cancer therapy.
Li Q; Lv X; Tang C; Yin C
Carbohydr Polym; 2022 Jul; 287():119315. PubMed ID: 35422284
[TBL] [Abstract][Full Text] [Related]
2. Enhanced antitumor efficacy of arginine modified amphiphilic nanoparticles co-delivering doxorubicin and iSur-pDNA via the multiple synergistic effect.
Song Y; Tang C; Yin C
Biomaterials; 2018 Jan; 150():1-13. PubMed ID: 29028548
[TBL] [Abstract][Full Text] [Related]
3. Enhanced antitumor efficacy of glutathione-responsive chitosan based nanoparticles through co-delivery of chemotherapeutics, genes, and immune agents.
Zhang L; Li Q; Chen J; Tang C; Yin C
Carbohydr Polym; 2021 Oct; 270():118384. PubMed ID: 34364626
[TBL] [Abstract][Full Text] [Related]
4. Co-Delivery of Doxorubicin and Survivin shRNA-Expressing Plasmid Via Microenvironment-Responsive Dendritic Mesoporous Silica Nanoparticles for Synergistic Cancer Therapy.
Li Z; Zhang L; Tang C; Yin C
Pharm Res; 2017 Dec; 34(12):2829-2841. PubMed ID: 28948461
[TBL] [Abstract][Full Text] [Related]
5. Enhanced antitumor efficacy of folate modified amphiphilic nanoparticles through co-delivery of chemotherapeutic drugs and genes.
Yu B; Tang C; Yin C
Biomaterials; 2014 Aug; 35(24):6369-78. PubMed ID: 24818887
[TBL] [Abstract][Full Text] [Related]
6. Co-delivery of doxorubicin and siRNA by all-trans retinoic acid conjugated chitosan-based nanocarriers for multiple synergistic antitumor efficacy.
Liu C; Tang C; Yin C
Carbohydr Polym; 2022 May; 283():119097. PubMed ID: 35153031
[TBL] [Abstract][Full Text] [Related]
7. Co-delivery of doxorubicin and interleukin-2 via chitosan based nanoparticles for enhanced antitumor efficacy.
Wu J; Tang C; Yin C
Acta Biomater; 2017 Jan; 47():81-90. PubMed ID: 27729232
[TBL] [Abstract][Full Text] [Related]
8. Targeted rod-shaped mesoporous silica nanoparticles for the co-delivery of camptothecin and survivin shRNA in to colon adenocarcinoma in vitro and in vivo.
Babaei M; Abnous K; Taghdisi SM; Taghavi S; Sh Saljooghi A; Ramezani M; Alibolandi M
Eur J Pharm Biopharm; 2020 Nov; 156():84-96. PubMed ID: 32882423
[TBL] [Abstract][Full Text] [Related]
9. Chemosensitizing indomethacin-conjugated chitosan oligosaccharide nanoparticles for tumor-targeted drug delivery.
Lee JY; Termsarasab U; Lee MY; Kim DH; Lee SY; Kim JS; Cho HJ; Kim DD
Acta Biomater; 2017 Jul; 57():262-273. PubMed ID: 28483700
[TBL] [Abstract][Full Text] [Related]
10. Dual-targeting nanoparticles with core-crosslinked and pH/redox-bioresponsive properties for enhanced intracellular drug delivery.
Zhao J; Yan C; Chen Z; Liu J; Song H; Wang W; Liu J; Yang N; Zhao Y; Chen L
J Colloid Interface Sci; 2019 Mar; 540():66-77. PubMed ID: 30634060
[TBL] [Abstract][Full Text] [Related]
11. Oral delivery of shRNA and siRNA via multifunctional polymeric nanoparticles for synergistic cancer therapy.
Han L; Tang C; Yin C
Biomaterials; 2014 May; 35(15):4589-600. PubMed ID: 24613049
[TBL] [Abstract][Full Text] [Related]
12. Smart co-delivery of plasmid DNA and doxorubicin using MCM-chitosan-PEG polymerization functionalized with MUC-1 aptamer against breast cancer.
Esmaeili Y; Dabiri A; Mashayekhi F; Rahimmanesh I; Bidram E; Karbasi S; Rafienia M; Javanmard SH; Ertas YN; Zarrabi A; Shariati L
Biomed Pharmacother; 2024 Apr; 173():116465. PubMed ID: 38507955
[TBL] [Abstract][Full Text] [Related]
13. Chitosan functionalized doxorubicin loaded poly(methacrylamide) based copolymeric nanoparticles for enhanced cellular internalization and in vitro anticancer evaluation.
Manhas P; Cokca C; Sharma R; Peneva K; Wangoo N; Sharma D; Sharma RK
Int J Biol Macromol; 2024 Feb; 259(Pt 2):129242. PubMed ID: 38199540
[TBL] [Abstract][Full Text] [Related]
14. Folic acid-chitosan conjugated nanoparticles for improving tumor-targeted drug delivery.
Song H; Su C; Cui W; Zhu B; Liu L; Chen Z; Zhao L
Biomed Res Int; 2013; 2013():723158. PubMed ID: 24282819
[TBL] [Abstract][Full Text] [Related]
15. Folate-decorated poly(3-hydroxybutyrate-co-3-hydroxyoctanoate) nanoparticles for targeting delivery: optimization and in vivo antitumor activity.
Zhang C; Zhang Z; Zhao L
Drug Deliv; 2016 Jun; 23(5):1830-7. PubMed ID: 26652055
[TBL] [Abstract][Full Text] [Related]
16. Design and evaluation of a novel potential carrier for a hydrophilic antitumor drug: Auricularia auricular polysaccharide-chitosan nanoparticles as a delivery system for doxorubicin hydrochloride.
Xiong W; Li L; Wang Y; Yu Y; Wang S; Gao Y; Liang Y; Zhang G; Pan W; Yang X
Int J Pharm; 2016 Sep; 511(1):267-275. PubMed ID: 27424168
[TBL] [Abstract][Full Text] [Related]
17. Catechol-modified chitosan/hyaluronic acid nanoparticles as a new avenue for local delivery of doxorubicin to oral cancer cells.
Pornpitchanarong C; Rojanarata T; Opanasopit P; Ngawhirunpat T; Patrojanasophon P
Colloids Surf B Biointerfaces; 2020 Dec; 196():111279. PubMed ID: 32750605
[TBL] [Abstract][Full Text] [Related]
18. pH-responsive selenium nanoparticles stabilized by folate-chitosan delivering doxorubicin for overcoming drug-resistant cancer cells.
Luesakul U; Puthong S; Neamati N; Muangsin N
Carbohydr Polym; 2018 Feb; 181():841-850. PubMed ID: 29254044
[TBL] [Abstract][Full Text] [Related]
19. Benzylguanidine and Galactose Double-Conjugated Chitosan Nanoparticles with Reduction Responsiveness for Targeted Delivery of Doxorubicin to CXCR 4 Positive Tumors.
Kong F; Tang C; Yin C
Bioconjug Chem; 2020 Oct; 31(10):2446-2455. PubMed ID: 32991164
[TBL] [Abstract][Full Text] [Related]
20. Cellular uptake and antitumor activity of DOX-hyd-PEG-FA nanoparticles.
Ye WL; Du JB; Zhang BL; Na R; Song YF; Mei QB; Zhao MG; Zhou SY
PLoS One; 2014; 9(5):e97358. PubMed ID: 24828815
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
